MD-IONQ
22.7.2024 14:01:26 CEST | Business Wire | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, recently unveiled expanded and accelerated 2025 technical milestones during an exclusive webinar hosted by CEO Peter Chapman, SVP of Engineering & Technology Dean Kassmann, and CMO Margaret Arakawa. IonQ established why it is the only quantum computing company designing and building best-in-class quantum computers that meet the requirements of performance, scalability, and enterprise-grade solutions that are critical for delivering unparalleled commercial advantage to customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722272052/en/
IonQ's three-pillar technology strategy to accelerate commercial advantage. (Graphic: Business Wire)
“It is imperative that we address performance, scale, and enterprise-grade quantum solutions simultaneously to achieve commercial advantage,” said Peter Chapman, President and CEO of IonQ. “Working to operationalize all three commercial advantage pillars is an industry-first that sets us apart. While other companies may hyperfocus on a single dimension, we focus on the complete picture, to ensure our quantum computing solutions are best-in-class and provide incomparable value to our customers.”
“Based on market demand, we’ve embarked on a path that no other commercial quantum computing company is taking, and we are committed to accelerating our quantum computing strategy as demonstrated by these ambitious goals,” said Dean Kassmann, SVP of Engineering & Technology at IonQ. “Our unique approach combines high performance single core operation, multi-core parallelism, modularity, photonic interconnects, novel technology, and systems engineering to deliver highly performant, scalable, and enterprise-grade quantum computers that drive meaningful advancements across various industries.”
Performance: Driving Efficiency and Unparalleled Flexibility
Performance improvements are core to IonQ’s technical roadmap, and the path toward meeting IonQ’s aggressive performance targets is clear. Native gate fidelity, architectural design decisions, and error correction will serve as levers to achieve these goals. IonQ is driving to improve native two-qubit gate performance to greater than three 9’s (>99.9%) in 2025, with further gains – fueled by the move to barium qubits – expected the following year. Performance improvements are also expected from highly efficient realizations of quantum algorithms that are enabled by IonQ’s low-shuttling, high-connectivity architectures. Lastly, the combination of high native gate fidelity and high connectivity provides unparalleled flexibility for implementing error correction and reducing time to solution. With this updated quantum architecture, IonQ expects to reach five 9’s (99.999%) in logical two-qubit gate fidelity by the end of 2025, opening up new application performance capabilities.
Scale: Architecture that Enables Expansive Growth
IonQ is pursuing scale in tandem with performance. IonQ’s north star is scalability at high performance, and modularity is a critical component of this strategy. IonQ’s approach to scale relies on making engineering and architectural decisions that support performance at large qubit counts. In addition, IonQ’s strategy for scaling takes advantage of multicore operation and photonically interconnected systems. Connecting multiple QPUs and quantum systems with photonic interconnects will enable IonQ to target 1000s of physical qubits in the future. These higher qubit counts will unlock new problem spaces and enable developers and researchers to tackle increasingly complex problems.
Enterprise-Grade: Meeting Real-World Needs
IonQ’s enterprise-grade approach readies its quantum systems for deployment across various sectors, focusing on manufacturability, deployability, and customer applications at scale. IonQ has already formed successful partnerships with organizations like the Naval Research Laboratory (NRL), Airbus, and Deutsches Elektronen-Synchrotron (DESY) – an internationally renowned center of fundamental research – as they focus on optimization problems and quantum chemistry and other important real-world applications. Additionally, IonQ is exploring a growing number of quantum algorithms across fields such as AI, financial services, and cybersecurity, reinforcing its commitment to real-world quantum technology applications.
Currently, IonQ operates two quantum data centers—one at its headquarters in College Park, Maryland, and another in Seattle, Washington, which the company opened earlier this year. Later this year, IonQ will expand its footprint by bringing its quantum data center in Basel, Switzerland, online. All of these locations are dedicated to supporting the needs of IonQ’s customers.
This momentum underscores IonQ's leadership in the quantum computing industry and robust industry demand. IonQ's enterprise strategy and expanding infrastructure highlight its dedication to unlocking commercial advantage by collaborating with industry leaders and making cutting-edge, well-balanced, quantum technology available ahead of schedule.
To learn more about IonQ and its latest system news and business developments, visit https://ionq.com/.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “accelerate,” “advance,” “dedicate,” “deploy,” “drive,” “enable,” “expand,” “expect,” “improve,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial advantage in the future, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, the effect of increased availability of customer support functions and enterprise-grade solutions, IonQ’s quantum computing capabilities and plans, access to IonQ’s quantum computers, increases in algorithmic qubit achievement, and the scalability, performance, and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates, including development of competing technologies; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722272052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
